Citations

Institution: Mayo Clinic Clear

Showing 10 of 108081 citations.

Treatment of Hodgkin's lymphoma in a patient with type III von Willebrand's disease
Kumar, Riten , Rodriguez, Vilmarie , Warad, Deepti , Kumar, Riten

Haemophilia | July 3, 2012 | Volume: 18 | Issue: 5 | Pages: No page available

10.1111/j.1365-2516.2012.02901.x | PMID 22757977 Get It

Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis
Mauguen, Audrey , Péchoux, C. Le , Saunders, Michele I., Schild, Steven E. , Turrisi, Andrew T., Baumann, Michaël , Sause, William T. , Belani, Chandra P. , Bonner, James A. , Zajusz, A. , Dahlberg, Suzanne E. , Nankivell, Matthew , Mandrekar, Sumithra J. , Behrendt, Katarzyna, Koch, Rainer , Bishop, James F., Dische, Stanley, Arriagada, R. , Ruysscher, Dirk De , Pignon, Jean‐Pierre , Ball, David , Paulus, Rebecca , Schild, Steven

Journal of Clinical Oncology | July 3, 2012 | Volume: 30 | Issue: 22 | Pages: 2788-2797

10.1200/jco.2012.41.6677 | PMID 22753901 Get It

Purpose In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or progression-free survival (PFS). The Meta-Analysis of Radiotherapy in Lung Cancer Collaborative Group decided to address the role of modified radiotherapy fractionation. Material and Methods We performed an individual patient data meta-analysis in patients with nonmetastatic lung cancer, which included trials comparing modified radiotherapy with conventional radiotherapy. Results In non–small-cell lung cancer (NSCLC; 10 trials, 2,000 patients), modified fractionation improved OS as compared with conventional schedules (hazard ratio [HR] = 0.88, 95% CI, 0.80 to 0.97; P = .009), resulting in an absolute benefit of 2.5% (8.3% to 10.8%) at 5 years. No evidence of heterogeneity between trials was found. There was no evidence of a benefit on PFS (HR = 0.94; 95% CI, 0.86 to 1.03; P = .19). Modified radiotherapy reduced deaths resulting from lung cancer (HR = 0.89; 95% CI, 0.81 to 0.98; P = .02), and there was a nonsignificant reduction of non–lung cancer deaths (HR = 0.87; 95% CI, 0.66 to 1.15; P = .33). In small-cell lung cancer (SCLC; two trials, 685 patients), similar results were found: OS, HR = 0.87, 95% CI, 0.74 to 1.02, P = .08; PFS, HR = 0.88, 95% CI, 0.75 to 1.03, P = .11. In both NSCLC and SCLC, the use of modified radiotherapy increased the risk of acute esophageal toxicity (odds ratio [OR] = 2.44 in NSCLC and OR = 2.41 in SCLC; P < .001) but did not have an impact on the risk of other acute toxicities. Conclusion Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC. As expected, there was increased acute esophageal toxicity.
Covered self-expanding metal stent use in the pancreatic duct: a case series
Akbar, Ali, Baron, T.

Endoscopy | July 2, 2012 | Volume: 44 | Issue: 09 | Pages: 869-873

10.1055/s-0032-1309835 | PMID 22752885 Get It

Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Critically Ill Patients
Afessa, Bekele, Azoulay, Élie

American Journal of Respiratory and Critical Care Medicine | July 2, 2012 | Volume: 186 | Issue: 1 | Pages: 8-10

10.1164/rccm.201204-0761ed | PMID 22753684 Get It

Infant With Right Leg Swelling, Tenderness, and Decreased Range of Motion
Alwan, Riham , Gupta, Nidhi , Karnati, Sreenivas, Sood, Beena G.

NeoReviews | July 2, 2012 | Volume: 13 | Issue: 7 | Pages: e455-e458

10.1542/neo.13-7-e455 Get It

Use of a clinical decision support system to increase osteoporosis screening
DeJesus, Ramona S.

Journal of Evaluation in Clinical Practice | July 2, 2012 | Volume: 18 | Issue: 4 | Pages: 926-926

10.1111/j.1365-2753.2012.01878.x | PMID 22747584 Get It

Acute Loss of Bladder Control in a Stroke of the Frontal Cortex
Woessner, Heidi, Barrett, Kevin M. , Vibhute, Prasanna

The Neurohospitalist | June 30, 2012 | Volume: 2 | Issue: 4 | Pages: 129-131

10.1177/1941874412450715 | PMID 23983877 Get It

Lesions of the medial frontal micturition center can result in the activation of the pontine and spinal micturition centers when the bladder is full, causing urinary incontinence. Recognition of acute bladder incontinence as part of a cortical hemispheric stroke syndrome may reduce the likelihood of false localization to the spinal cord in patients with acute ischemic stroke eligible for acute reperfusion therapy. We describe a case of urinary incontinence due to anterior cerebral artery infarction and discuss the cortical localization of voluntary bladder control to the anterior cingulate gyrus, inferior frontal gyrus, middle frontal gyrus, and superior frontal gyrus.
Future Neurohospitalist
Freeman, William D. , Barrett, Kevin M. , Vatz, Kenneth A., Demaerschalk, Bart M. , Freeman, William D

The Neurohospitalist | June 30, 2012 | Volume: 2 | Issue: 4 | Pages: 132-143

10.1177/1941874412450714 | PMID 23983878 Get It

Despite the growing demand for emergency neurological evaluations and neurohospitalists, the supply of neurologists remains relatively fixed over time. Telemedicine is a unique tool that has the ability to put a medical specialist like a neurologist in 2 places in a relatively short period of time, expanding expertise in many rural and in some underserved urban facilities that would ordinarily be devoid of such expertise. Teleneurology is a branch of telemedicine that consults and practices through remote neurological evaluation. Telestroke is defined as remote stroke evaluation. The demand for timely neurological evaluation, especially acute stroke evaluation and treatment with intravenous recombinant tissue plasminogen activator (IV rtPA), continues to fuel the growth of neurohospitalists, telestroke, and teleneurology services. Remote, rural, or underserved urban emergency departments and hospitals which are unable to successfully recruit a neurologist or neurohospitalist to provide this service are uniquely suited to a teleneurology option. The number of private practices and academic centers providing telestroke services has grown significantly in the past decade with continued growth expected. We describe the benefits and drawbacks of teleneurology/telestroke, as well as other practical aspects for the teleneurohospitalist.
Allograft Versus Autograft in Posterior Cruciate Ligament Reconstruction: An Evidence-Based Systematic Review
Hudgens, Joshua L., Gillette, Blake P., Krych, Aaron J. , May, Jedediah H., Levy, Bruce A. , Stuart, Michael J. , Krych, Aaron J

Journal of Knee Surgery | June 29, 2012 | Volume: 26 | Issue: 02 | Pages: 109-116

10.1055/s-0032-1319778 | PMID 23288765 Get It

Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans
Coombs, Catherine C. , Rassenti, Laura Z., Falchi, Lorenzo , Strom, Sara S., Weinberg, J. Brice , Lanasa, Mark C., Slager, Susan L. , Ferrajoli, Alessandra , Kipps, Thomas J.

Blood | June 29, 2012 | Volume: 120 | Issue: 8 | Pages: 1687-1690

10.1182/blood-2012-02-408799 | PMID 22745306 Get It

AbstractThe incidence of chronic lymphocytic leukemia (CLL) is significantly lower in African Americans than whites, but overall survival is inferior. The biologic basis for these observations remains unexplored. We hypothesized that germline genetic predispositions differ between African Americans and whites with CLL and yield inferior clinical outcomes among African Americans. We examined a discovery cohort of 42 African American CLL patients ascertained at Duke University and found that the risk allele frequency of most single nucleotide polymorphisms known to confer risk of development for CLL is significantly lower among African Americans than whites. We then confirmed our results in a distinct cohort of 68 African American patients ascertained by the CLL Research Consortium. These results provide the first evidence supporting differential genetic risk for CLL between African Americans compared with whites. A fuller understanding of differential genetic risk may improve prognostication and therapeutic decision making for all CLL patients.